Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnologystartup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located.[3] Atlas raised its thirteenth fund totaling $450 million in March 2022,[4] after raising its Opportunity Fund II totaling $300 million in September 2021.[5]
History
Atlas has invested in over 150 life sciences startups since it began investing in the sector in 1990.[citation needed] Atlas invests in a range of therapeutic areas and modalities, including immuno-oncology, autoimmunity/inflammation, neuroscience, gene/cell therapy and editing, and anti-infectives. Atlas' current portfolio comprises biotech companies including Accent Therapeutics, Aerovate Therapeutics, Affinia Therapeutics, Akero Therapeutics, Arkuda Therapeutics, AVROBIO, Be Biopharma, Chroma Medicine, Day One Biopharmaceuticals, Disc Medicine, Dyne Therapeutics, Generation Bio, HotSpot Therapeutics, Ikena Oncology, Intellia Therapeutics, Kinaset Therapeutics, Korro Bio, Kymera Therapeutics, Mariana Oncology, Matchpoint Therapeutics, Nimbus Therapeutics, Pheon Therapeutics, Obsidian Therapeutics, Q32 Bio, Rectify Pharmaceuticals, Remix Therapeutics, Replimune, Scorpion Therapeutics, Sionna Tehrapeutics, Synlogic; Third Harmonic Bio, Triana Biomedicines, Versanis Bio, Vigil Neuroscience, and Xilio Therapeutics. Notable prior exits from Atlas’ life sciences portfolio include Actelion, Adnexus Therapeutics, Alnylam Pharmaceuticals, Annovation Biopharma, ArQule, Arrow Therapeutics, Arteaus Therapeutics, Avila Therapeutics, Cadent Therapeutics, Disarm Therapeutics, CoStim Pharmaceuticals, Crucell, deCODE genetics, Delinia, Exelixis, IFM Therapeutics Inc., Micromet, Momenta Pharmaceuticals, MorphoSys, Nimbus Apollo, Novexel, Padlock Therapeutics, Rodin Therapeutics, Stromedix, Translate Bio, and U3 Pharma.[6]
Originally formed in 1980 in Amsterdam as a subsidiary of NMB Bank, now part of ING Group, Atlas historically invested in both life sciences and information technology startup companies. In October 2014, Atlas announced its shift to a biotech-only venture capital firm, with the technology-focused investment team forming a new firm, Accomplice, to continue investing in information technology startups.[7][8] Previously as a diversified firm, Atlas had raised over $3.0 billion of investor commitments across nine venture capital funds. The firm raised $705 million for its 2000-vintage fifth fund, $600 million for its 2001-vintage sixth fund, $385 million for its 2006-vintage seventh fund, $283 million for its 2009-vintage eighth fund, and $265 million for its 2013-vintage ninth fund.[9][10] At its largest, the firm held European offices in London, Paris and Munich,[11] and a West Coast office based in Seattle, Washington, in addition to the Boston-area headquarters. Today, the firm operates from a single office in Cambridge, Massachusetts.[12][13]
In 2015 Atlas raised its first biotech-dedicated fund, Fund X, at $280 million. In 2017, Atlas Venture announced it had raised Fund XI at $350 million in capital to invest in early stage biotech companies in the U.S. and around the world.[14] In January 2019, Atlas Venture announced its Opportunity Fund I raised $250 million.[15] In June 2020, Atlas Venture announced its Fund XII raised $400 million.[16]
Related Research Articles
Sofinnova is the name shared by two venture capital firms, Sofinnova Partners and Sofinnova Ventures. The name Sofinnova is a contraction of the French, "Société de Financement de l’Innovation" or, Innovation Venture Capital Company. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. The two firms have raised ~$4B since inception and have generally shared a similar investment strategy of financing projects and ideas in the life sciences and technology sectors. The two firms distinguish themselves on the basis of their target geographies, stage of investment, and sectors. They have been independent entities since 1997.
GV Management Company, L.L.C. is a venture capital investment arm of Alphabet Inc., founded by Bill Maris, that provides seed, venture, and growth stage funding to technology companies. Founded as Google Ventures in 2010, the firm has operated independently of Google, Alphabet's search and advertising division, since 2015. GV invests in startup companies in a variety of fields ranging from the Internet, software, and hardware to life science, healthcare, artificial intelligence, transportation, cyber security and agriculture. It has helped finance more than 300 companies that include Uber, Nest, Slack, and Flatiron Health.
TCA Venture Group is the leading source of funding to early-stage companies in Southern California. In 2023, TCA had about 400 members. In August 2014, an analysis by CB Insights ranked TCA No.1 out of 370 angel groups on “Network Centrality” and No. 5 overall in “Investor Mosaic.”
Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.
The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine.
New Enterprise Associates (NEA) is an American-based venture capital firm. NEA focuses investment stages ranging from seed stage through growth stage across an array of industry sectors. With ~$25 billion in committed capital, NEA is one of the world's largest venture capital firms.
Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.
Francesco De Rubertis is a partner at medicxi, a venture capital firm with offices in London, Jersey and Geneva, having co-founded the firm in February 2016. Prior to that he was a partner at another venture capital firm, Index Ventures, having led the firm's efforts to establish its life sciences practice after joining in 1997.
Brian Singerman is a partner at Founders Fund, a San Francisco-based venture capital firm with over $11 billion under management.
Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
SOSV is a venture capital firm that provides pre-seed, seed, venture and growth stage funding to startups in the technology sector. The company conducts seed accelerator programs in Asia and the United States of America.
Gelesis is a biotechnology company located in Boston, Massachusetts that developed the weight loss device Gelesis100 (Plenity) for use in overweight and obesity. The company produces Gelesis100, which is a superabsorbent hydrogel capsule that expands in the stomach, creating a feeling of fullness, helping people reduce the amount of food they eat. The company was founded in 2006 to develop medical devices and treatments for obesity.
Asset-centricity is an approach to investing in the life sciences field with a focus on key assets, such as a pharmaceutical molecule that could form the basis for a novel new drug which has already been identified, rather than on discovering such assets through basic research & development.
Pitango VC, established in 1993, is Israel's largest venture capital fund with over $2.8 billion under management. Pitango VC invests through three dedicated funds, Pitango First, Pitango HealthTech, and Pitango Growth. Pitango invests in startups around the world, in domains such as Vertical SaaS, Digital Health, Deep Tech, FinTech & InsureTech, Devops, Generative AI, Web3, and FoodTech.
Abingworth LLP is a transatlantic bioscience investment firm founded in 1973 by a pair of London stockbrokers, Peter Dicks and Hon. Anthony Montagu. Abingworth had initially sought to extend its investments into the biotechnology industry in the late 1980s, and has subsequently been investing in life science and healthcare services companies since at least 2001, and had expanded to include information technology firm investments by 2016.
Foresite Capital is an American venture capital and growth equity firm headquartered in San Francisco. As of March 2021, the company had raised four funds: Foresite Capital Fund I, II, III, IV and V.
Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.
Greater Boston, primarily Boston and Cambridge, is home to more than 1,000 biotechnology companies, ranging from small start-ups to billion-dollar pharmaceutical companies. The many universities in the area give the region a large network of scientists.
OrbiMed is an American investment firm based in New York City, United States. It is focused on making public and private investments in the Healthcare and Biotechnology industries. OrbiMed is considered to be one of the largest dedicated healthcare investment firms in the world.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
